Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

NCT07396090 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL: eDC-KRAS vaccine
DRUG: Tislelizumab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences